Merkel Cell Carcinoma in a Nine-Year-Old Girl Abstract #634

Introduction: Merkel cell carcinoma (MCC) of the skin is a rare neuroendocrine tumor characterized by its rapid growth and aggressive clinical behavior. MCC is a typical tumor of older age (average age is 65 years). In children and adolescents less than 20 years of age, it is extremely rare. Information regarding MCC in childhood can be found in the literature only in the form of individual case reports. Due to the rarity of MCC in the young population, any clinical studies or treatment recommendations in these patients are missing.
Aim(s): We are presenting a 9-year-old girl with recurrent MCC with 11 years overall survival after treatment including surgery, radiotherapy, chemotherapy and differentiation therapy. According to our knowledge, it is most likely the 10th known case of Merkel cell carcinoma in the young generation and the fifth reported case of MCC under 15 years of age.
Materials and methods: Case report of 9-year-old girl with recurrent and metastatic MCC of the neck. Combined therapy (surgery, multiagent CHT, RT) + retinoids have been used.
Conference: 10th Annual ENETS Conference (2013)
Category: Clinical cases/reports
Presenting Author: MD, PhD Viera - Bajciova

To read results and conclusion, please login ...

Further abstracts you may be interested in

#69 Frequent biological association of Merkel cell polyomavirus with Merkel cell carcinomas
Introduction: Merkel cell polyomavirus (MCPyV) DNA has been detected by PCR in 75–100% of Merkel cell carcinomas (MCC), an aggressive neuroendocrine skin cancer. MCPyV is a 5.4 kb DNA virus that expresses tumor (T) antigen in tumor tissues.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Ernst-Jan M Speel
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
#652 Neuroendocrine Neoplasms in Childhood and Adolescents
Introduction: NEN are very rare tumors in children and adolescents with predominance in adolescent girls. The annual incidence is about 1.14:1 million. The most frequent localization is appendix. Bronchial NEN, even extremly rare, is the most frequent primary epithelial lung tumor in children.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD,PhD Viera - Bajciova
Authors: Bajciova V, Tuma J, Kren L, Prasek J, ...
#703 Cutaneous Merkel Cell Carcinoma Treatment: Our Experience
Introduction: Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr Francesca Bruder
Authors: Bruder F, Barca M, Porcu S G, Dessena M, ...
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team